Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDL NASDAQ:JAN OTCMKTS:OPTI NASDAQ:REVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.07$1.24$0.77▼$2.63$89.57M1.03412,433 shs767,552 shsJANJanOne$2.57$0.22▼$5.26$20.03M2.16229,417 shs139,500 shsOPTIOptec International$0.00-21.4%$0.00$0.00▼$0.00$13KN/A1.05 million shs152,545 shsREVBRevelation Biosciences$1.92-4.0%$2.67$1.90▼$60.48$3.26M-0.04293,594 shs250,867 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics-1.83%-3.60%-5.31%-26.71%-54.08%JANJanOne0.00%0.00%0.00%0.00%0.00%OPTIOptec International-22.22%-30.00%-6.67%-22.22%+180.00%REVBRevelation Biosciences-19.03%-28.57%-17.36%-16.04%-95.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.07$1.24$0.77▼$2.63$89.57M1.03412,433 shs767,552 shsJANJanOne$2.57$0.22▼$5.26$20.03M2.16229,417 shs139,500 shsOPTIOptec International$0.00-21.4%$0.00$0.00▼$0.00$13KN/A1.05 million shs152,545 shsREVBRevelation Biosciences$1.92-4.0%$2.67$1.90▼$60.48$3.26M-0.04293,594 shs250,867 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics-1.83%-3.60%-5.31%-26.71%-54.08%JANJanOne0.00%0.00%0.00%0.00%0.00%OPTIOptec International-22.22%-30.00%-6.67%-22.22%+180.00%REVBRevelation Biosciences-19.03%-28.57%-17.36%-16.04%-95.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 3.33Buy$8.00644.19% UpsideJANJanOne 0.00N/AN/AN/AOPTIOptec International 0.00N/AN/AN/AREVBRevelation Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.22 per shareN/AJANJanOne$39.61M0.00N/AN/A($0.67) per share0.00OPTIOptec InternationalN/AN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/A$9.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$26.77M-$0.34N/AN/AN/AN/A-232.26%-158.19%11/13/2025 (Estimated)JANJanOne-$7.81MN/A0.00N/AN/AN/A-359.71%-70.26%N/AOPTIOptec InternationalN/AN/A0.00∞N/AN/AN/AN/AN/AREVBRevelation Biosciences-$15.04M-$68.61N/AN/AN/AN/A-240.27%-148.95%11/14/2025 (Estimated)Latest JAN, CRDL, OPTI, and REVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CRDLCardiol Therapeutics-$0.11-$0.07+$0.04-$0.07N/AN/A8/7/2025Q2 2025REVBRevelation Biosciences-$4.46-$7.01-$2.55-$7.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/AJANJanOneN/AN/AN/AN/AN/AOPTIOptec InternationalN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol Therapeutics0.012.462.46JANJanOneN/A0.150.15OPTIOptec InternationalN/AN/AN/AREVBRevelation BiosciencesN/A3.423.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%JANJanOne6.27%OPTIOptec InternationalN/AREVBRevelation Biosciences12.80%Insider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%JANJanOne3.00%OPTIOptec International50.34%REVBRevelation Biosciences2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics2083.71 million79.32 millionNot OptionableJANJanOne1708.98 million8.71 millionNot OptionableOPTIOptec International111.65 millionN/ANot OptionableREVBRevelation Biosciences101.70 million1.66 millionNot OptionableJAN, CRDL, OPTI, and REVB HeadlinesRecent News About These CompaniesRevelation Biosciences announces exercise of warrants for $9.6M in proceedsSeptember 11 at 12:03 PM | msn.comRevelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross ProceedsSeptember 11 at 8:30 AM | accessnewswire.comARevelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical DataSeptember 10 at 7:20 AM | accessnewswire.comAReminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line DataSeptember 9 at 4:55 PM | accessnewswire.comARevelation Biosciences announces topline results from PRIME studySeptember 9 at 11:46 AM | msn.comRevelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical StudySeptember 9 at 8:00 AM | accessnewswire.comARevelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025August 8, 2025 | businesswire.comRevelation Biosciences Inc. Completes Dosing of Patients in PRIME StudyJuly 16, 2025 | businesswire.comRevelation Biosciences to implement 1-for-3 reverse stock splitJuly 2, 2025 | investing.comRevelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025 - MorningstarJuly 2, 2025 | morningstar.comMRevelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025July 1, 2025 | businesswire.comRevelation Biosciences Inc News (REVB) - Investing.comJune 24, 2025 | investing.comRevelation Biosciences, Inc. (REVB) Raises $4M in Public OfferingMay 31, 2025 | finance.yahoo.comRevelation Biosciences sets terms for $4 million public offeringMay 30, 2025 | investing.comRevelation Biosciences, Inc. (REVB) Raises $4M in Public OfferingMay 29, 2025 | insidermonkey.comRevelation Biosciences, Inc. Announces Closing of $4 Million Public OfferingMay 29, 2025 | businesswire.comRevelation Biosciences, Inc. Announces Pricing of $4 Million Public OfferingMay 29, 2025 | finance.yahoo.comRevelation Biosciences board member steps down amid new focusMay 25, 2025 | uk.investing.comRevelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of DirectorsMay 23, 2025 | businesswire.comREVB On Track and Exploring New MarketsMay 9, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCan Identity Security Fuel CrowdStrike’s Next Growth Phase?By Chris Markoch | August 22, 2025Microsoft Stock: Bullish Bets Pile Up Before SeptemberBy Chris Markoch | August 18, 2025Smaller Industrials Names Seeing Surging Growth: Here's WhyBy Nathan Reiff | August 30, 2025How ServiceNow Is Turning AI Strategy Into Real RevenueBy Jeffrey Neal Johnson | August 22, 2025Petrobras: Why Traders Are Betting Big on a Shareholder PayoutBy Jeffrey Neal Johnson | August 26, 2025JAN, CRDL, OPTI, and REVB Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$1.07 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.08 +0.00 (+0.47%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.JanOne NASDAQ:JANJanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.Optec International OTCMKTS:OPTI$0.0011 0.00 (-21.43%) As of 01:42 PM EasternOptec International, Inc. engages in selling and marketing optimized fuel maximizer units in North America and internationally. It markets optimized fuel maximizer for passenger vehicles, intermediate/medium duty trucks, off-road equipment, generator systems, heavy duty diesel on-road vehicles, and transportation refrigeration units. The company was formerly known as Green Meadow Products, Inc. and changed its name to Optec International, Inc. in August 2017. Optec International, Inc. was founded in 2012 and is based in Carlsbad, California.Revelation Biosciences NASDAQ:REVB$1.92 -0.08 (-4.00%) Closing price 04:00 PM EasternExtended Trading$1.92 0.00 (-0.26%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Why Micron Stock Could Outperform NVIDIA in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
